AltPep, a privately held biomedical company focused on diagnosing and treating Central Nervous System amyloid disorders, starting with Alzheimer's Disease, announced it closed a $23.150 million Series A investment round. Matrix Capital Management led the investment, with significant participation by Alexandria Venture Investments.

AltPep's biomedical technology was developed at the University of Washington laboratory of AltPep Founder and CEO, Valerie Daggett, Ph.D., and targets the misfolded forms of amyloid proteins. This platform technology has the potential to transform the diagnosis and treatment of Alzheimer's Disease and other CNS-mediated disorders.